Do analysts prefer SPRO or LPCN?

Lipocine has a consensus target price of $15.00, suggesting a potential upside of 591.24%. Given Lipocine's higher probable upside, analysts plainly believe Lipocine is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, MNOV or LPCN?

Lipocine has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediciNova $410K 172.27 -$12M -$0.21 N/A Lipocine $1.98M 9.03 -$9.63M -$1.79 N/A

Is MNOV or LPCN more profitable?

Lipocine has a net margin of -755.39% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets MediciNova -1,168.70% -26.51% -24.39% Lipocine -755.39% -64.75% -57.62%

Does the media prefer MNOV or LPCN?

In the previous week, MediciNova had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for MediciNova and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.32 beat MediciNova's score of 0.88 indicating that Lipocine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lipocine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELOX or LPCN?

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.32 beat Eloxx Pharmaceuticals' score of 0.62 indicating that Lipocine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lipocine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, LPCN or TLPH?

Lipocine has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.98M 9.03 -$9.63M -$1.79 N/A Talphera $30K 2,076.40 -$14.29M -$0.27 N/A

Is LPCN or TLPH more profitable?

Talphera has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -755.39% -64.75% -57.62% Talphera N/A -87.28% -51.36%

Lipocine (LPCN) Competitors

$2.17 -0.06 (-2.69%)

As of 08/28/2026 04:00 PM Eastern

Compare

LPCN vs. SPRO, MNOV, ELOX, TLPH, and HRTX

Should you buy Lipocine stock or one of its competitors? Lipocine's main competitors and comparable companies include Spero Therapeutics (SPRO), MediciNova (MNOV), Eloxx Pharmaceuticals (ELOX), Talphera (TLPH), and Heron Therapeutics (HRTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lipocine compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Lipocine has a consensus target price of $15.00, suggesting a potential upside of 591.24%. Given Lipocine's higher probable upside, analysts plainly believe Lipocine is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Lipocine had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Lipocine and 1 mentions for Spero Therapeutics. Lipocine's average media sentiment score of 1.32 beat Spero Therapeutics' score of 0.94 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
Spero Therapeutics	Positive
Lipocine	Positive

Spero Therapeutics has a net margin of 24.90% compared to Lipocine's net margin of -755.39%. Spero Therapeutics' return on equity of 16.17% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	16.17%	12.57%
Lipocine	-755.39%	-64.75%	-57.62%

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by insiders. Comparatively, 4.7% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spero Therapeutics has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.05	$8.57M	$0.11	10.91
Lipocine	$1.98M	9.03	-$9.63M	-$1.79	N/A

Spero Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Summary

Spero Therapeutics beats Lipocine on 10 of the 15 factors compared between the two stocks.

How does Lipocine compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

MediciNova has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

9.9% of MediciNova shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 4.7% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, MediciNova had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for MediciNova and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.32 beat MediciNova's score of 0.88 indicating that Lipocine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lipocine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lipocine has a net margin of -755.39% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Lipocine	-755.39%	-64.75%	-57.62%

MediciNova currently has a consensus target price of $8.33, suggesting a potential upside of 480.72%. Lipocine has a consensus target price of $15.00, suggesting a potential upside of 591.24%. Given Lipocine's higher possible upside, analysts plainly believe Lipocine is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Lipocine has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	172.27	-$12M	-$0.21	N/A
Lipocine	$1.98M	9.03	-$9.63M	-$1.79	N/A

Summary

MediciNova beats Lipocine on 11 of the 17 factors compared between the two stocks.

How does Lipocine compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Eloxx Pharmaceuticals has a beta of -1863.11, meaning that its stock price is 186,411% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Eloxx Pharmaceuticals presently has a consensus price target of $41.50, indicating a potential upside of 175.38%. Lipocine has a consensus price target of $15.00, indicating a potential upside of 591.24%. Given Lipocine's higher probable upside, analysts clearly believe Lipocine is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Eloxx Pharmaceuticals and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.32 beat Eloxx Pharmaceuticals' score of 0.62 indicating that Lipocine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lipocine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eloxx Pharmaceuticals has higher revenue and earnings than Lipocine. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	9.57	-$5.99M	-$1.54	N/A
Lipocine	$1.98M	9.03	-$9.63M	-$1.79	N/A

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Eloxx Pharmaceuticals' return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Lipocine	-755.39%	-64.75%	-57.62%

Summary

Eloxx Pharmaceuticals beats Lipocine on 12 of the 17 factors compared between the two stocks.

How does Lipocine compare to Talphera?

Lipocine (NASDAQ:LPCN) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Lipocine currently has a consensus target price of $15.00, indicating a potential upside of 591.24%. Talphera has a consensus target price of $3.00, indicating a potential upside of 150.00%. Given Lipocine's higher possible upside, analysts plainly believe Lipocine is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Lipocine has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Talphera has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, Lipocine had 1 more articles in the media than Talphera. MarketBeat recorded 2 mentions for Lipocine and 1 mentions for Talphera. Lipocine's average media sentiment score of 1.32 beat Talphera's score of 0.65 indicating that Lipocine is being referred to more favorably in the media.

Company	Overall Sentiment
Lipocine	Positive
Talphera	Positive

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 4.7% of Lipocine shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Talphera has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Talphera	N/A	-87.28%	-51.36%

Lipocine has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.03	-$9.63M	-$1.79	N/A
Talphera	$30K	2,076.40	-$14.29M	-$0.27	N/A

Summary

Lipocine and Talphera tied by winning 8 of the 16 factors compared between the two stocks.

How does Lipocine compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Heron Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

In the previous week, Lipocine had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 2 mentions for Lipocine and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.89 beat Lipocine's score of 1.32 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Very Positive
Lipocine	Positive

Heron Therapeutics presently has a consensus target price of $2.00, indicating a potential upside of 512.37%. Lipocine has a consensus target price of $15.00, indicating a potential upside of 591.24%. Given Lipocine's higher possible upside, analysts clearly believe Lipocine is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Heron Therapeutics has a net margin of -22.52% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Lipocine	-755.39%	-64.75%	-57.62%

Lipocine has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.40	-$20.19M	-$0.19	N/A
Lipocine	$1.98M	9.03	-$9.63M	-$1.79	N/A

Summary

Heron Therapeutics beats Lipocine on 10 of the 16 factors compared between the two stocks.

Get Lipocine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LPCN vs. The Competition

Export

Metric	Lipocine	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.89M	$12.17B	$7.21B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-1.21	787.65	273.16	25.42
Price / Sales	9.03	755.84	630.81	94.42
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	0.83	10.49	11.08	6.36
Net Income	-$9.63M	$2.83B	$3.48B	$349.79M
7 Day Performance	3.83%	0.39%	0.13%	-0.80%
1 Month Performance	2.84%	5.34%	7.08%	4.13%
1 Year Performance	-25.43%	6.05%	24.67%	15.17%

Lipocine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LPCN Lipocine	3.0668 of 5 stars	$2.17 -2.7%	$15.00 +591.2%	-25.4%	$17.89M	$1.98M	N/A	10	News Coverage Positive News
SPRO Spero Therapeutics	1.4576 of 5 stars	$1.21 -0.8%	N/A	-42.0%	$70.46M	$42.96M	11.00	150
MNOV MediciNova	2.0257 of 5 stars	$1.42 -4.1%	$8.33 +486.9%	+9.5%	$69.89M	$410K	N/A	10
ELOX Eloxx Pharmaceuticals	4.2761 of 5 stars	$16.00 -13.7%	$41.50 +159.4%	N/A	$64.64M	$6.36M	N/A	N/A
TLPH Talphera	2.7939 of 5 stars	$1.23 -2.4%	$3.00 +143.9%	+121.8%	$63.85M	$30K	N/A	19

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LPCN) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lipocine (LPCN) Competitors

LPCN vs. SPRO, MNOV, ELOX, TLPH, and HRTX

How does Lipocine compare to Spero Therapeutics?

Summary

How does Lipocine compare to MediciNova?

Summary

How does Lipocine compare to Eloxx Pharmaceuticals?

Summary

How does Lipocine compare to Talphera?

Summary

How does Lipocine compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lipocine (LPCN) Competitors

LPCN vs. SPRO, MNOV, ELOX, TLPH, and HRTX

How does Lipocine compare to Spero Therapeutics?

Do analysts prefer SPRO or LPCN?

Does the media favor SPRO or LPCN?

Is SPRO or LPCN more profitable?

Do insiders & institutionals hold more shares of SPRO or LPCN?

Which has stronger valuation and earnings, SPRO or LPCN?

Which has more risk & volatility, SPRO or LPCN?

Summary

How does Lipocine compare to MediciNova?

Which has more volatility and risk, MNOV or LPCN?

Do institutionals & insiders believe in MNOV or LPCN?

Does the media prefer MNOV or LPCN?

Is MNOV or LPCN more profitable?

Do analysts rate MNOV or LPCN?

Which has stronger earnings and valuation, MNOV or LPCN?

Summary

How does Lipocine compare to Eloxx Pharmaceuticals?

Which has more risk & volatility, ELOX or LPCN?

Do analysts rate ELOX or LPCN?

Does the media prefer ELOX or LPCN?

Which has better valuation and earnings, ELOX or LPCN?

Do institutionals and insiders believe in ELOX or LPCN?

Is ELOX or LPCN more profitable?

Summary

How does Lipocine compare to Talphera?

Do analysts prefer LPCN or TLPH?

Which has more volatility and risk, LPCN or TLPH?

Does the media refer more to LPCN or TLPH?

Do insiders and institutionals have more ownership in LPCN or TLPH?

Is LPCN or TLPH more profitable?

Which has stronger valuation and earnings, LPCN or TLPH?

Summary

How does Lipocine compare to Heron Therapeutics?

Which has more volatility and risk, HRTX or LPCN?

Does the media prefer HRTX or LPCN?

Do analysts rate HRTX or LPCN?

Do insiders & institutionals believe in HRTX or LPCN?

Is HRTX or LPCN more profitable?

Which has preferable valuation & earnings, HRTX or LPCN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools